Provided by Tiger Trade Technology Pte. Ltd.

Akebia Therapeutics

0.8994
+0.02653.04%
Post-market: 0.8914-0.0080-0.89%19:55 EDT
Volume:16.70M
Turnover:14.97M
Market Cap:240.93M
PE:-11.57
High:0.9259
Open:0.8601
Low:0.8396
Close:0.8729
52wk High:4.08
52wk Low:0.8227
Shares:267.88M
Float Shares:259.80M
Volume Ratio:5.21
T/O Rate:6.43%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.0777
EPS(LYR):-0.0208
ROE:-78.96%
ROA:2.02%
PB:8.80
PE(LYR):-43.27

Loading ...

Company Profile

Company Name:
Akebia Therapeutics
Exchange:
NASDAQ
Establishment Date:
2007
Employees:
194
Office Location:
245 First Street,Suite 1400,Cambridge,Massachusetts,United States
Zip Code:
02142
Fax:
617 871 2099
Introduction:
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.